Silo Pharma Inc (SILO)

[TRADER99]

These whatsapp groups are pumping to sell the dilution lol

[Monksdream]

SILO under $3

[Monksdream]

Offering killed the momentum

[TommyBoyTrader9460]

$SILO

$SILO Continues to break out strong..up 12 percent on strong volume in Premarket.. pic.twitter.com/SdVgkHDCo9

— Chris from Massachusetts AKA TommyboyTrader (@autumnsdad1) July 19, 2024

[DOGONE]

Should continue for days.

[Dantheoneman]

Weeeeeee

[Monksdream]

Early Barchart 100, quote delayed, real time at 9:45
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

[Invest-in-America]

SILO: Mr. 'Subs', & Mr. 'Aw', & Mr. 'Glenn'!!!! (You guys are my DDAmanda-like SCANNERS!!! And ya all have me on iHub's IGNORE, so ya can't even SEE my posts!!! LOVE this stuff!!!)

PS: At least SILO's 'Old Timers' stuff made MICE feel less stressful behind THEIR 'Old Timer's Mice' affliction!! Heck, a step in the right direction, RIGHT???

[glenn1919]

SILO........................................https://stockcharts.com/h-sc/ui?s=SILO&p=W&b=5&g=0&id=p86431144783

[subslover]

Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic
Agreement enhances Company’s intellectual property portfolio

SARASOTA, FL, July 16, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into an exclusive global license agreement to further develop, manufacture, and commercialize its Alzheimer’s drug SPC-14. Silo intends to utilize the FDA’s streamlined 505(b)(2) pathway for SPC-14, which would shorten clinical timelines and reduce drug development costs.

“In our view, our exclusive license for SPC-14 gives us the potential to meet a large unmet medical need. If approved, we believe SPC-14 could bring hope and relief for many families and patients. Early pre-clinical studies have shown stress reduction and cognitive improvement,” said Silo CEO Eric Weisblum.

Silo Pharma recently announced a similar exclusive license agreement for its lead drug candidate, SPC-15, an intranasal treatment for stress-induced affective disorders and PTSD.

The global Alzheimer’s disease therapeutics market size is forecasted to exceed $30.8 billion by 2033, with a CAGR of 18.8% from 2024 to 2033 1 . Rising prevalence of the disease in the expanding elderly population and advancements in neurological research are expected to drive market growth.

[Awl416]

Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic

[Monksdream]

SILO under $2

[Awl416]

Silo Pharma Announces Positive Results for Intranasal PTSD Treatment

[Awl416]

Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic

[Monksdream]

SILO 10Q due 3/26
Next day settlement 5/28 per SEC mandate

[Monksdream]

SILO under $2

[Monksdream]

SILO under $2

[Michael TRed]

Low floater. Could see 5$ quick

[Michael TRed]

2$ +

[Michael TRed]

Load

[Monksdream]

SILO

[subslover]

Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders
Study data to determine potential delivery partners

ENGLEWOOD CLIFFS, NJ, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has advanced the formulation development for its therapeutic drug, SPC-15. The liquid nasal formulation will be used in SPC-15’s novel protocol intended for treatment and prevention of anxiety, PTSD, and other stress related disorders. The formulation development was in accordance with the Company’s sponsored research agreement and option with Columbia University. Linearity, accuracy, and repeatability were achieved in the feasibility study.

“The progress of our feasibility study investigating dose strengths of SPC-15 is a significant advancement in our development work with this pipeline candidate,” said Eric Weisblum, Chief Executive Officer of Silo Pharma. “Results of the feasibility study will determine our selection of the manufacturing processes, and we are currently in discussions with potential delivery partners. We may also use the feasibility data for upcoming studies related to our SPC-14 therapeutic targeting Alzheimer’s disease.”

In May 2023, Silo Pharma was awarded a U.S. Patent titled “Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders,” with claims protecting the key technology behind SPC-15 and further drug discovery.

About Silo Pharma

Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information visit www.silopharma.com

[MasterBlastr]

Looks the the garbage squad got a hold of this . . .

[Awl416]

Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic

[Garbage2Gucci]

$SILO gaining traction on news #PTSD #Anxiety

Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders
https://finance.yahoo.com/news/silo-pharma-commences-formulation-spc-130000596.html

Data to Support Alzheimer’s Study

ENGLEWOOD CLIFFS, NJ, April 19, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has commenced development of a novel formulation as a targeted prophylactic treatment, designated as SPC-15, intended for stress, anxiety, and PTSD.

Development of the drug formulation is pursuant to the Company’s sponsored research agreement with Columbia University. Preclinical studies in the field suggest that SPC-15 could be a promising therapeutic target for the treatment of cognitive impairment, PTSD, and stress-related disorders.

“We are advancing our development of SPC-15 through this formulation and feasibility study investigating dose strengths and delivery,” said Eric Weisblum, Chief Executive Officer of Silo Pharma. “The SPC-15 treatment protocol predicts levels of severity or progression of stress-related disorders and their metabolomic biomarkers’ response to pharmacological treatments. Based on our own research to date coupled with published preclinical data, we believe SPC-15 could have a profound impact on treating stress and anxiety disorders including PTSD, we will further use this data to help us with our upcoming studies related to SPC-14 Alzheimer’s asset.”

Targeted by SPC-15, anxiety, PTSD, and other stress-related disorders are becoming more frequent in Americans aged 18+. According to the World Health Organization in 2019, 300+ million people were living with an anxiety disorder, and according to the National Center for PTSD, around 12 million adults in the U.S. alone are reported to have PTSD., According to Fortune Business Insights, the global treatment market size for anxiety disorders and depression is projected to reach $13.0 billion in 2027.

Silo Pharma was recently granted a U.S. patent covering SPC-15 as a method for the treatment and prevention of stress-induced affective disorders in females.

About Silo Pharma

Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information visit www.silopharma.com

Forward-Looking Statements

All statements other than statements of historical fact in this announcement are forward-looking statements that involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC.

Contact
800-705-0120
[e-mail]

World Health Organization; Mental disorders. June 2022.
U.S. Department of Veterans Affairs, PTSD: National Center for PTSD; How Common Is PTSD in Adults?

[TheFinalCD]

SILO NEWS TODAY POPS TO 2.50 DROPS TO 1.75



https://finviz.com/quote.ashx?t=SILO&ty=c&ta=1&p=d

[glenn1919]

SILO.............................https://finviz.com/quote.ashx?t=SILO&ty=c&ta=1&p=d

[TheFinalCD]

https://finviz.com/quote.ashx?t=SILO&ty=c&ta=1&p=d

[glenn1919]

SILO..................................https://stockcharts.com/h-sc/ui?s=SILO&p=W&b=5&g=0&id=p86431144783

[tw0122]

Let’s go share buyback 1 million shares

[Awl416]

News

[Laster]

Really hope people listened and actually read the news.

[IVANj]

Lots of vol…. Took 3.15 for a bounce

[Invest-in-America]

FUNNY!!!

[Invest-in-America]

Was just joking, Dude!! (I fully GET all of your reply there, & THANKS!!)

[Laster]

Animal data is no real news.
Stock should drift back and close the gap eventually.
Definitely not a runner on THAT news.
JMO.

[KOmani]

I mean the reason the price broke down was shorting.

Whether those shorts have non-public information is what makes it scummy.

[Laster]

Typical trader response. No clue about how biotechs work.
This animal study announced is just a pump.
Only if I could short a stock. This would have been the one when it was over $6.
Sorry BRO!!!!

[Invest-in-America]

SILO: Heck, that all "Humans" are too, Bro!!!

[Laster]

Just an animal study.
OMG.
This run will be very short lived.
JMO.

[tw0122]

6.91 Silo Pharma shares are trading higher after the company announced study results of SPU-21 for arthritis. The company said SPU-21 is effective in controlling arthritis

[tw0122]

Up 50% nice

[Jaydixson1]

Is this a good one

[Pirateshipatbay]

This looks like buys are coming in here 5.25

[subslover]

R/S are hot? I must have eaten the wrong mushrooms like the ancient Greeks!

[Renee]

SILO moved to the Nasdaq from the OTC:

https://otce.finra.org/otce/dailyList?viewType=Deletions

[Renee]

SILO: one for 50 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

[PennyMaster]

$SILO Nice News out!! Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine

ENGLEWOOD CLIFFS, N.J, July 27, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announced that its topically administered Ketamine reached a positive end point in an animal study.

Silo’s formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, and mechanical hyperalgesia was reduced on day seven at the pre-dose time point. These results indicate that the dosing of Ketamine using a patent protected delivery system with Silo Pharma’s partner, Zylo Therapeutics, yielded positive results in reducing neuropathic nerve pain in a small animal study.

Eric Weisblum, CEO of Silo Pharma, commented, “These positive results of our study show that Silo is able to successfully formulate and deliver ketamine topically at reduced dosage to achieve its endpoint of pain reduction. This data is extremely promising for patients suffering from Fibromyalgia and Rheumatoid Arthritis. Additionally, I am delighted to report that Day seven and Day nine scores averaged zero (no erythema or swelling present) for all groups, which bodes extremely well for our planned toxicology study.”

About Silo Pharma
Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information, visit www.silopharma.com

Safe Harbor and Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events, or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.

Investor Relations Contact:

Hayden IR
Brett Maas
646-536-7331
Email: [e-mail]

https://finance.yahoo.com/news/silo-pharma-announces-positive-results-121500306.html

[subslover]

Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine
Press Release | 07/27/2022
Silo shows reversal of allodynia and hyperalgesia using its selected formulation and partnered, patented delivery system

ENGLEWOOD CLIFFS, N.J, July 27, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announced that its topically administered Ketamine reached a positive end point in an animal study.

Silo’s formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, and mechanical hyperalgesia was reduced on day seven at the pre-dose time point. These results indicate that the dosing of Ketamine using a patent protected delivery system with Silo Pharma’s partner, Zylo Therapeutics, yielded positive results in reducing neuropathic nerve pain in a small animal study.

Eric Weisblum, CEO of Silo Pharma, commented, “These positive results of our study show that Silo is able to successfully formulate and deliver ketamine topically at reduced dosage to achieve its endpoint of pain reduction. This data is extremely promising for patients suffering from Fibromyalgia and Rheumatoid Arthritis. Additionally, I am delighted to report that Day seven and Day nine scores averaged zero (no erythema or swelling present) for all groups, which bodes extremely well for our planned toxicology study.”

About Silo Pharma
Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information, visit www.silopharma.com

[R4000]

Wonder how/if the uplist to the Nas is going... either way I think there is a lot of upside here imo.